Research
Molecular
Insulin sensitizers such as PPARγ (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown beneficial effects on both NASH and liver fibrosis.
Consider insulin sensitizers as part of the treatment plan for NASH and liver fibrosis.
StrongSupportsmedium confidence
Insulin sensitizers such as PPARγ (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown some beneficial effects on both NASH and liver fibrosis.
Why this rating
The claim is based on clinical evidence regarding treatment efficacy.
Source
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou · Diabetes Obesity and Metabolism · 2022
reviewCited 49×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →